Toxicities of hypofractionated radiotherapy after breast‐conserving surgery: a literature review
Song Yuchun, Wang Shulian
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Abstract:Hypofractionated radiotherapy, which provides equivalent efficacy and dose not increase toxicity compared with conventional fractionated radiotherapy following breast‐conserving surgery, has become a preferred choice for whole breast irradiation. Given the low local recurrence risk and long survival time for early breast cancer survivors, radiation‐associated toxicities are the focus of clinical practice. However, in the era of hypofractionated radiotherapy, the risk factors for radiation‐associated toxicity remain undefined and further research is warranted. In this review, we aim to provide an overview of the toxicities of hypofractionated radiotherapy following breast‐conserving surgery.
Song Yuchun,Wang Shulian. Toxicities of hypofractionated radiotherapy after breast‐conserving surgery: a literature review[J]. Chinese Journal of Radiation Oncology, 2022, 31(12): 1179-1184.
[1] Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials[J]. Lancet, 2011,378(9804):1707-1716. DOI: 10.1016/S0140-6736(11)61629-2. [2] Yarnold J, Ashton A, Bliss J, et al.Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial[J]. Radiother Oncol, 2005,75(1):9-17. DOI: 10.1016/j.radonc.2005.01.005. [3] Smith BD, Bellon JR, Blitzblau R, et al.Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline[J]. Pract Radiat Oncol, 2018,8(3):145-152. DOI: 10.1016/j.prro.2018.01.012. [4] Owen JR, Ashton A, Bliss JM, et al.Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial[J]. Lancet Oncol, 2006,7(6):467-471. DOI: 10.1016/S1470-2045(06)70699-4. [5] Haviland JS, Owen JR, Dewar JA, et al.The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials[J]. Lancet Oncol, 2013,14(11):1086-1094. DOI: 10.1016/S1470-2045(13)70386-3. [6] Whelan TJ, Pignol JP, Levine MN, et al.Long-term results of hypofractionated radiation therapy for breast cancer[J]. N Engl J Med, 2010,362(6):513-520. DOI: 10.1056/NEJMoa0906260. [7] Offersen BV, Alsner J, Nielsen HM, et al.Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial[J]. J Clin Oncol, 2020,38(31):3615-3625. DOI: 10.1200/JCO.20.01363. [8] Shaitelman SF, Lei X, Thompson A, et al. Three-year outcomes with hypofractionated versus conventionally fractionated whole-breast irradiation: results of a randomized, noninferiority clinical trial[J]. J Clin Oncol, 2018,36(35):JCO1800317. DOI: 10.1200/JCO.18.00317. [9] Wang SL, Fang H, Hu C, et al.Hypofractionated versus conventional fractionated radiotherapy after breast-conserving surgery in the modern treatment era: a multicenter, randomized controlled trial from China[J]. J Clin Oncol, 2020,38(31):3604-3614. DOI: 10.1200/JCO.20.01024. [10] Arsenault J, Parpia S, Goldberg M, et al.Acute toxicity and quality of life of hypofractionated radiation therapy for breast cancer[J]. Int J Radiat Oncol Biol Phys, 2020,107(5):943-948. DOI: 10.1016/j.ijrobp.2020.03.049. [11] Brunt AM, Haviland JS, Sydenham M, et al.Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer[J]. J Clin Oncol, 2020,38(28):3261-3272. DOI: 10.1200/JCO.19.02750. [12] Murray Brunt A, Haviland JS, Wheatley DA, et al.Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial[J]. Lancet, 2020,395(10237):1613-1626. DOI: 10.1016/S0140-6736(20)30932-6. [13] Haviland JS, Mannino M, Griffin C, et al.Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: results from the UK START (standardisation of breast radiotherapy) trials[J]. Radiother Oncol, 2018,126(1):155-162. DOI: 10.1016/j.radonc.2017.10.033. [14] Burstein HJ, Curigliano G, Thürlimann B, et al.Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021[J]. Ann Oncol, 2021,32(10):1216-1235. DOI: 10.1016/j.annonc.2021.06.023. [15] Meattini I, Becherini C, Boersma L, et al.European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer[J]. Lancet Oncol, 2022,23(1):e21-e31. DOI: 10.1016/S1470-2045(21)00539-8. [16] Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer[J]. J Natl Cancer Inst, 2002,94(15):1143-1150. DOI: 10.1093/jnci/94.15.1143. [17] Yarnold J, Bentzen SM, Coles C, et al.Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities[J]. Int J Radiat Oncol Biol Phys, 2011,79(1):1-9. DOI: 10.1016/j.ijrobp.2010.08.035. [18] Shaitelman SF, Schlembach PJ, Arzu I, et al.Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: a randomized clinical trial[J]. JAMA Oncol, 2015,1(7):931-941. DOI: 10.1001/jamaoncol.2015.2666. [19] Lee BM, Chang JS, Kim SY, et al.Hypofractionated radiotherapy dose scheme and application of new techniques are associated to a lower incidence of radiation pneumonitis in breast cancer patients[J]. Front Oncol, 2020,10:124. DOI: 10.3389/fonc.2020.00124. [20] Chan EK, Woods R, Virani S, et al.Long-term mortality from cardiac causes after adjuvant hypofractionated vs. conventional radiotherapy for localized left-sided breast cancer[J]. Radiother Oncol, 2015,114(1):73-78. DOI: 10.1016/j.radonc.2014.08.021. [21] James M, Swadi S, Yi M, et al.Ischaemic heart disease following conventional and hypofractionated radiation treatment in a contemporary breast cancer series[J]. J Med Imaging Radiat Oncol, 2018,62(3):425-431. DOI: 10.1111/1754- 9485.12712. [22] Byun HK, Chang JS, Im SH, et al.Risk of lymphedema following contemporary treatment for breast cancer: an analysis of 7617 consecutive patients from a multidisciplinary perspective[J]. Ann Surg, 2021,274(1):170-178. DOI: 10.1097/SLA.0000000000003491. [23] Dorn PL, Corbin KS, Al-Hallaq H, et al.Feasibility and acute toxicity of hypofractionated radiation in large-breasted patients[J]. Int J Radiat Oncol Biol Phys, 2012,83(1):79-83. DOI: 10.1016/j.ijrobp.2011.05.074. [24] Patel AK, Ling DC, Richman AH, et al.Hypofractionated whole-breast irradiation in large-breasted women-is there a dosimetric predictor for acute skin toxicities?[J]. Int J Radiat Oncol Biol Phys, 2019,103(1):71-77. DOI: 10.1016/j.ijrobp.2018.08.024. [25] Vasiljevic D, Arnold C, Neuman D, et al.Occurrence of pneumonitis following radiotherapy of breast cancer - a prospective study[J]. Strahlenther Onkol, 2018,194(6):520-532. DOI: 10.1007/s00066-017-1257-z. [26] Marks LB, Bentzen SM, Deasy JO, et al.Radiation dose-volume effects in the lung[J]. Int J Radiat Oncol Biol Phys, 2010,76(3 Suppl):S70-76. DOI: 10.1016/j.ijrobp.2009. 06.091. [27] van den Bogaard VA, Ta BD, van der Schaaf A, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures[J]. J Clin Oncol, 2017,35(11):1171-1178. DOI: 10.1200/JCO.2016.69.8480. [28] Taylor CW, Povall JM, McGale P, et al. Cardiac dose from tangential breast cancer radiotherapy in the year 2006[J]. Int J Radiat Oncol Biol Phys, 2008,72(2):501-507. DOI: 10.1016/j.ijrobp.2007.12.058. [29] 陈偲晔, 王淑莲, 唐玉, 等. 乳腺癌保乳术后大分割放疗亚临床心脏损伤的前瞻性研究[J].中华肿瘤杂志,2020,42(6):456-462. DOI: 10.3760/cma.j.cn112152-20200131-00057. Chen SY, Wang SL, Tang Y, et al.Subclinical heart injury in patients receiving hypofractionated radiotherapy after breast conserving surgery: a preliminary analysis of prospective study[J].Chin J Oncol,2020,42(6):456-462. DOI: 10.3760/cma.j.cn112152-20200131-00057. [30] Skyttä T, Tuohinen S, Boman E, et al.Troponin T-release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy[J]. Radiat Oncol, 2015,10:141. DOI: 10.1186/s13014-015-0436-2. [31] Berg M, Lorenzen EL, Jensen I, et al.The potential benefits from respiratory gating for breast cancer patients regarding target coverage and dose to organs at risk when applying strict dose limits to the heart: results from the DBCG HYPO trial[J]. Acta Oncol, 2018,57(1):113-119. DOI: 10.1080/0284186X.2017.1406139. [32] Wang SL, Fang H, Song YW, et al.Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial[J]. Lancet Oncol, 2019,20(3):352-360. DOI: 10.1016/S1470-2045(18)30813-1. [33] Liu L, Yang Y, Guo Q, et al.Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review[J]. Radiat Oncol, 2020,15(1):17. DOI: 10.1186/s13014-020-1463-1. [34] Naoum GE, Roberts S, Brunelle CL, et al.Quantifying the impact of axillary surgery and nodal irradiation on breast cancer-related lymphedema and local tumor control: long-term results from a prospective screening trial[J]. J Clin Oncol, 2020,38(29):3430-3438. DOI: 10.1200/JCO.20.00459. [35] Gross JP, Lynch CM, Flores AM, et al.Determining the organ at risk for lymphedema after regional nodal irradiation in breast cancer[J]. Int J Radiat Oncol Biol Phys, 2019,105(3):649-658. DOI: 10.1016/j.ijrobp.2019.06.2509. [36] Healy E, Jhawar S, Beyer S, et al. Abstract P3-19-08: breast cancer related lymphedema in patients undergoing RNI: is the axillary lateral vessel thoracic junction an organ-at-risk?[J]. Cancer Res, 2022,82(4_Suppl): P3-19-08. DOI: org/10.1158/1538-7445.SABCS21-P3-19-08. [37] Johansson S, Svensson H, Denekamp J.Timescale of evolution of late radiation injury after postoperative radiotherapy of breast cancer patients[J]. Int J Radiat Oncol Biol Phys, 2000,48(3):745-750. DOI: 10.1016/s0360-3016(00)00674-x. [38] Leong N, Truong PT, Tankel K, et al.Hypofractionated nodal radiation therapy for breast cancer was not associated with increased patient-reported arm or brachial plexopathy symptoms[J]. Int J Radiat Oncol Biol Phys, 2017,99(5):1166-1172. DOI: 10.1016/j.ijrobp.2017.07.043. [39] Gałecki J, Hicer-Grzenkowicz J, Grudzień-Kowalska M, et al.Radiation-induced brachial plexopathy and hypofractionated regimens in adjuvant irradiation of patients with breast cancer--a review[J]. Acta Oncol, 2006,45(3):280-284. DOI: 10.1080/02841860500371907. [40] Johansson S, Svensson H, Denekamp J.Dose response and latency for radiation-induced fibrosis, edema, and neuropathy in breast cancer patients[J]. Int J Radiat Oncol Biol Phys, 2002,52(5):1207-1219. DOI: 10.1016/s0360-3016(01)02743-2.